The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 3, 2005, Pages 356-360

  Mousa, Shaker A ^a   O'Connor, Laura J ^a   Bergh, Joel J ^b   Davis, Faith B ^b   Scanlan, Thomas S ^c   Davis, Paul J ^b,d,e  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STRATTON VA MEDICAL CENTER   (United States)

^e WADSWORTH CENTER   (United States)

Author keywords

v 3 integrin; Angiogenesis; Fibroblast growth factor 2; Mitogen activated protein kinase; Thyroid hormone analogues

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AGAROSE; FIBROBLAST GROWTH FACTOR 2; GC 1; INTEGRIN; LEVOTHYROXINE; LIOTHYRONINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROPYLTHIOURACIL; RECEPTOR BLOCKING AGENT; TETRAIODOTHYROACETIC ACID; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VITRONECTIN RECEPTOR BLOCKING AGENT; XT 199;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CHORIOALLANTOIS; DRUG BINDING; DRUG STRUCTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

ACETIC ACIDS; ANIMALS; CELL MEMBRANE; CHICK EMBRYO; CHORION; FIBROBLAST GROWTH FACTOR 2; INDICATORS AND REAGENTS; INTEGRIN ALPHAVBETA3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOLS; REGIONAL BLOOD FLOW; THYROID HORMONE RECEPTORS BETA; THYROXINE;

EID: 24344506562     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000175438.94906.a0     Document Type: Article

References (19)

1. Davis FB, Mousa SA, O'Connor L, et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res. 2004;94:1500-1506.
2. 2--ATPase activity. Life Sci. 1982;30:675-682.
3. Lin H-Y, Davis FB, Gordinier JK, et al. Thyroid hormone induces activation of mitogen-activated protein kinase in cultured cells. Am J Physiol. 1999;276:C1014-C1024.
4. Chin WW, Yen PM. Molecular mechanisms of nuclear thyroid hormone action. In: Braverman LE, ed. Diseases of the Thyroid. Totowa, NJ: Humana Press, 2003:1-17.
5. Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. Thyroid. 2002; 12:459-466.
6. Lin H-Y, Zhang S, West BL, et al. Identification of the putative MAP kinase docking site in the thyroid hormone receptor-β1 DNA binding domain: functional consequences of mutations at the docking site. Biochemistry. 2003;42:7571-7579.
7. Baxter JD, Webb P, Grover G, et al. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab. 2004;15:154-157.
8. Chiellini G, Apriletti JW, Yoshihara HA, et al. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol. 1998;5:299-306.
9. Moore JMR, Galicia SJ, McReynolds AC, et al. Quantitative proteomics of the thyroid hormone receptor-coregulator interactions. J Biol Chem. 2004;279:27584-27590.
10. Davis PJ, Shih A, Lin H-Y, et al. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J Biol Chem. 2000;275: 38032-38039.
11. Naik MU, Mousa SA, Parkos CA, et al. Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood. 2003;102:2108-2114.
12. Farach-Carson MC, Davis PJ. Steroid hormone interactions with target cells: cross talk between membrane and nuclear pathways. J Pharmacol Exp Ther. 2003;307:839-845.
13. Safer JD, Crawford TM, Holick MF. A role for thyroid hormone in wound healing through keratin gene expression. Endocrinology. 2004;145: 2357-2361.
14. Bergh JJ, Lin H-Y, Mohamed SN, et al. L-Thyroxine induces mitogen-activated protein kinase activation via binding to integrin αVβ3. Proceedings of the 76th Annual Meeting of the American Thyroid Association, September 2004, program number 26.
15. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem. 2000;275:21785-21788.
16. Bowers JL, Tyulmenkov VV, Jernigan SC, et al. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. Endocrinology. 2000;141:3657-3667.
17. Farwell AP, Tranter MP, Leonard JL. Thyroxine-dependent regulation of integrin-laminin interactions in astrocytes. Endocrinology. 1995;136: 3909-3915.
18. Baxter JD, Dillmann WH, West BL, et al. Selective modulation of thyroid hormone receptor action. J Steroid Biochem Mol Biol. 2001;76: 31-42.
19. Xiong J-P, Stehle T, Ahang R, et al. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science. 2002;296:151-155.